Table 2. Univariate analysis of risk factors for nephrotoxicity.
| Characteristic | OR | 95% CI | P-value |
|---|---|---|---|
| Age ≥ 67 years | 0.83 | 0.60–1.14 | P = 0.25 |
| Sex (male) | 0.91 | 0.66–1.27 | P = 0.57 |
| Body weight ≥ 57.2 kg | 1.31 | 0.95–1.81 | P = 0.10 |
| Serum creatinine ≥ 0.68 mg/dL | 0.63 | 0.45–0.87 | P < 0.01† |
| CCr < 88.8 mL/min | 0.58 | 0.42–0.81 | P < 0.01† |
| Duration of therapy ≥ 10 days | 2.27 | 1.63–3.16 | P < 0.01† |
| Concomitant medications | |||
| NSAIDs | 1.24 | 0.90–1.70 | P = 0.19 |
| Furosemide | 3.63 | 2.61–5.05 | P < 0.01† |
| Amphotericin B | 6.23 | 2.61–14.91 | P < 0.01† |
| Aminoglycoside antibiotics | 1.95 | 0.69–5.47 | P = 0.21 |
| Piperacillin–Tazobactam | 2.96 | 2.06–4.27 | P < 0.01† |
| Vasopressor drugs | 3.12 | 2.12–4.61 | P < 0.01† |
| Residence in intensive care unit | 1.72 | 1.12–2.63 | P = 0.01† |
| Average VCM trough concentration ≥ 13 mg/L | 3.28 | 2.35–4.58 | P < 0.01† |
| With loading dose | 0.72 | 0.45–1.15 | P = 0.17 |
Creatinine clearance: CCr, Vancomycin: VCM, Odds ratio: OR, 95% Confidence interval: 95% CI
†P-values ≤ 0.05 were included in the artificial neural network and multiple logistic regression analysis.